VTVT

A week ago, vTv Therapeutics Inc. (NASDAQ:VTVT) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. Statutory earnings performance was extremely strong, with revenue of US$37m beating expectations by 268% and earnings per share (EPS) of US$1.65, an impressive 273%ahead of expectations. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. After the latest results, the consensus from vTv Therapeutics' six analysts is for revenues of US$20.0m in 2026, which would reflect a stressful 46% decline in revenue compared to the last year of performance. Earnings are expected to tip over into lossmaking territory, with the analysts forecasting statutory losses of -US$1.30 per share in 2026. Before this latest report, the consensus had been expecting revenues of US$10.0m and US$2.40 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven. View our latest analysis for vTv Therapeutics There was no major change to the consensus price target of US$53.00, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on vTv Therapeutics, with the most bullish analyst valuing it at US$67.00 and the most bearish at US$44.00 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await vTv Therapeutics shareholders. One way to get more context on these forecasts is to look at how they compa...

Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout HIGH POINT, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. The Company continues to advance its Phase 3 CATT1 trial, with enrollment on track for completion in the third quarter of 2026. vTv expects its current cash position to be sufficient to fund operations through the anticipated CATT1 topline data readout, positioning the Company to reach this key value inflection point with cash currently on hand. “We are executing with focus and discipline as we advance cadisegliatin, a potentially transformative, first-in-class oral therapy for people living with type 1 diabetes,” said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. “Enrollment in our Phase 3 CATT1 trial continues to progress steadily, supported by expanded site activation and strong engagement from both investigators and patients. Importantly, with our recently strengthened balance sheet, we are well-capitalized to deliver on completion of enrollment and the anticipated topline data readout and drive long-term value for shareholders.” Recent Company Highlights Phase 3 CATT1 Trial Progressing: Enrollment is ongoing in the Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in individuals with T1D. The Company expects to complete enrollment in the third quarter of 2026, supported by expanded site activation and increased investigator and patient engagement. License Amendment Adds Non-Dilutive Capital: In February 2026, the Company announced an amendment to its license agreement with Newsoara Biopharma, granting Newsoara global rights to the Company's highly selective PDE4 inhibitor, HPP737. Under the amended agreement, the Company received a $20.0 million upfront payment and is eligible to receive up to approximately $50.0 million in development milestones, up to $65.0 million in sales milestones, and tiered royalties on net sales. T...

HIGH POINT, N.C. (AP) — HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. (VTVT) on Wednesday reported first-quarter earnings of $24.1 million. On a per-share basis, the High Point, North Carolina-based company said it had profit of $1.65. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 34 cents per share. The biopharmaceutical company posted revenue of $36.8 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VTVT at https://www.zacks.com/ap/VTVT

HIGH POINT, N.C. (AP) — HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. (VTVT) on Tuesday reported a loss of $7.1 million in its fourth quarter. On a per-share basis, the High Point, North Carolina-based company said it had a loss of 58 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 98 cents per share. For the year, the company reported a loss of $27 million, or $3.20 per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VTVT at https://www.zacks.com/ap/VTVT

Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026 Strengthened balance sheet provides funding runway well past the anticipated CATT1 Phase 3 topline readout HIGH POINT, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent corporate developments. “In 2025, vTv delivered meaningful clinical and corporate progress that positions us for a highly productive 2026,” said Paul Sekhri, Chairman, President and CEO of vTv Therapeutics. “During the course of the year, we initiated patient dosing in the Phase 3 CATT1 trial evaluating cadisegliatin as an adjunct to insulin for the treatment of type 1 diabetes, strengthened our balance sheet with an $80.0 million financing with leading healthcare investors, and continued to expand our intellectual property estate supporting cadisegliatin. In early 2026, we secured an additional $20.0 million in non-dilutive funding.” “Looking ahead, 2026 remains an important year for vTv as we advance the CATT1 Phase 3 trial. Following study start-up, while patient enrollment progressed more slowly than initially anticipated, we expanded the number of participating sites, and increased physician and patient engagement efforts, resulting in a significant acceleration in enrollment momentum. Based on current trends, we expect to complete enrollment in the third quarter of 2026. Cadisegliatin continues to show promise as a meaningful oral adjunctive therapy for people living with type 1 diabetes, and we look forward to completing the trial and bringing this important potential therapy to market.” Recent Company Highlights Amended Licensing Agreement with Newsoara Biopharma Inc., Resulting in $20.0 million Upfront Milestone Payment to vTv. In February 2026, the Company announced it expanded its license agreement with Newsoara to include global rights to the Company’s highly selective PDE4 inhibitor, HPP737. Pursuant to the amended license agreement, News...

HIGH POINT, N.C. (AP) — HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. (VTVT) on Thursday reported a loss of $8.7 million in its third quarter. On a per-share basis, the High Point, North Carolina-based company said it had a loss of $1.08. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VTVT at https://www.zacks.com/ap/VTVT

Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041 HIGH POINT, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the third quarter ended September 30, 2025, and provided an update on recent corporate developments. “The third quarter saw a series of meaningful achievements,” said Paul Sekhri, Chairman, President and CEO of vTv Therapeutics. “During the quarter, we randomized our first patient in the Phase 3 CATT1 trial, expanded our U.S. patent estate for cadisegliatin, and successfully completed an $80 million private placement financing with leading healthcare investors. With a strengthened balance sheet, we are positioned to continue advancing our cadisegliatin program and remain on track to report topline results from the CATT1 trial in the second half of 2026.” Recent Company Highlights Strengthened Balance Sheet with $80 Million Private Placement. In September 2025, vTv announced the successful closing of an $80 million private placement with new and existing healthcare investors as well as the T1D Fund. The proceeds are expected to fund the ongoing CATT1 Phase 3 trial and continued development of the cadisegliatin program for the treatment of T1D. First Study Participant Randomized in Cadisegliatin Phase 3 Trial. In August 2025, vTv Therapeutics announced that the first study participant was randomized in the Company’s CATT1 Phase 3 trial evaluating cadisegliatin as an adjunctive therapy to insulin for the treatment of T1D. Topline data from the study is expected in the second half of 2026. Patent Allowance for Crystalline Salt Form of Cadisegliatin. In August 2025, the United States Patent and Trademark Office allowed claims for a patent application directed to compositions of matter of crystalline forms of salts and co-crystals of cadisegliatin. The patent term runs through 2041. Third Quarter 2025 Financ...

HIGH POINT, N.C. (AP) — HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. (VTVT) on Tuesday reported a loss of $6 million in its second quarter. On a per-share basis, the High Point, North Carolina-based company said it had a loss of 92 cents. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VTVT at https://www.zacks.com/ap/VTVT

• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 • Cadisegliatin intellectual property portfolio expanded • Leadership team strengthened HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent corporate developments. “The randomization of the first participant in our CATT1 Phase 3 trial earlier this month reflects our continued momentum in advancing cadisegliatin,” said Paul Sekhri, Chairman, President and CEO of vTv Therapeutics. “Cadisegliatin is designed to selectively activate glucokinase in the liver, a differentiated approach that may improve glycemic control and reduce the risk of hypoglycemia when used alongside insulin. Hypoglycemic episodes remain frequent, life-disruptive, and sometimes life-threatening for people with type 1 diabetes. We believe cadisegliatin could play a meaningful role in addressing this large unmet medical need.” Recent Company Highlights First Study Participant Randomized in Cadisegliatin Phase 3 Trial. In August 2025, vTv Therapeutics announced that the first study participant was randomized in the Company’s CATT1 Phase 3 Trial evaluating cadisegliatin as an adjunctive therapy to insulin for the treatment of T1D. Topline data from the study is expected in the second half of 2026. (link to press release) Patent Allowance for Crystalline Salt Form of Cadisegliatin. In August 2025, the United States Patent and Trademark Office allowed claims for a patent application directed to compositions of matter of crystalline forms of salts and co-crystals of cadisegliatin. The patent term runs through 2041. (link to press release) Corporate Presentation at HCW@Home. In June 2025, the Company participated in a virtual fireside chat as part of the H.C. Wainwright HCW@Home series. (link to webcast replay) Appointment of Chief Financial Officer. In May 2025, vTv Therapeutics appointed Michael Tung, MD, MBA, as Chief Financial Officer. Dr. Tung brings over 20 years of financial manag...

HIGH POINT, N.C. (AP) — HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. (VTVT) on Thursday reported a loss of $5.1 million in its first quarter. On a per-share basis, the High Point, North Carolina-based company said it had a loss of 77 cents. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VTVT at https://www.zacks.com/ap/VTVT

Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2025, and provided an update on recent corporate developments. “Our late stage cadisegliatin program is advancing with potential to be the first oral adjunct therapy for T1D,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. “We reinitiated screening in our Phase 3 CATT1 study and, based upon the recent protocol amendment to shorten the study from 12 to 6 months, we expect topline Phase 3 data for cadisegliatin in the second half of 2026.” Recent Company Highlights Screening Reinitiated for Cadisegliatin Phase 3 Trial. In May 2025, vTv Therapeutics announced that screening has been reinitiated in the Company’s CATT1 phase 3 trial evaluating cadisegliatin as an adjunctive therapy to insulin for treatment of type 1 diabetes (T1D). Topline data from the study is expected in the second half of 2026. Protocol Amendment for CATT1 Phase 3 Trial. In April, the Company submitted a protocol amendment to reduce the overall duration of the CATT1 trial from 12 to 6 months, which will expedite time to topline data by forgoing the additional 6-month safety assessment with no impact on original key endpoints. Also based on the amendment, continuous glucose monitors (CGM) will now be provided to participants. First Quarter 2025 Financial Results Cash Position: The Company’s cash position as of March 31, 2025, was $31.1 million compared to $36.7 million as of December 31, 2024. Research & Development (R&D) Expenses: R&D expenses were $2.8 million and $2.6 million in each of the three months ended March 31, 2025, and 2024, respectively. The increase reflects higher indirect costs and other project-related expenses. This was partially offset by lower spending on cadisegliatin, primarily due to reduced clinical trial costs and drug manufacturing costs and lower spending on other projects. General & Administrative (...

Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2024, and provided an update on recent corporate developments. “We are thrilled our cadisegliatin clinical program can resume following the lifting of the clinical hold by the U.S. Food and Drug Administration (FDA). We expect to resume our Phase 3 CATT1 trial in patients with T1D in the second quarter of 2025 following submission of a protocol amendment shortening the trial duration from 12 to 6 months,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. “Importantly, this amendment accelerates the time to topline data and allows initiation of our required pivotal studies sooner by forgoing an additional 6-month safety assessment with no impact on the original key endpoints of the study.” Mr. Sekhri continued, “As we approach our next stage of growth, we are pleased to have strengthened our commercial leadership with the appointment of Martin Lafontaine as our Chief Commercial Officer. Martin brings a wealth of commercial experience in diabetes which will position us for success as we prepare to further progress across our registrational program for cadisegliatin.” Recent Company Highlights Clinical Hold Lifted for Cadisegliatin Program. In March 2025, vTv Therapeutics announced that the clinical hold placed by the FDA in July 2024 on the cadisegliatin clinical program was lifted on March 14, 2025, following the Company’s submission of a complete response letter. The CATT1 Phase 3 trial is expected to resume in Q2 2025. Planned Submission of CATT1 Phase 3 Trial Protocol Amended. The Company plans to amend the protocol for the CATT1 Phase 3 trial in patients with T1D to reduce the duration of the trial from twelve months to six months by forgoing an additional 6-month safety assessment with...